 | Your browser does not display parts of our website correctly. We use the latest technology available to provide you with a high quality experience; please upgrade your browser to its latest version to view the contents properly: |
NeoGenomics, Inc. (NEO) operates a network of cancer-focused genetic testing laboratories in the United States; and laboratories in Switzerland and Singapore.
It operates in two segments, Clinical Services and Pharma Services.
The company's laboratories provide genetic and molecular testing services to hospitals, pathologists, oncologists, urologists, other clinicians and researchers, pharmaceutical firms, academic centers, and other clinical laboratories.
It offers cytogenetics testing services to study normal and abnormal chromosomes and their relationship to diseases; fluorescence in-situ hybridization testing services that focus on detecting and locating the presence or absence of specific DNA sequences and genes on chromosomes; flow cytometry testing services to measure the characteristics of cell populations; immunohistochemistry and digital imaging testing services to localize proteins in cells of a tissue section, as well as to allow clients to see and utilize scanned slides, and perform quantitative analysis for various stains; and molecular testing services, which focus on the analysis of DNA and RNA, and the structure and function of genes at the molecular level.
The company also provides pathology consultation services for clients in which its pathologists review surgical samples on a consultative basis; and testing services in support of its pharmaceutical clients' oncology programs covering discovery and commercialization, as well as acts as a reference laboratory supplying anatomic pathology testing services. Shares are heading higher in an upward trading channel. The lower bundary of the channel coincides with the stock's 50-day moving average.
Neogenomics (NEO) reported 1st Quarter March 2019 earnings of $0.05 per share on revenue of $95.6 million. The consensus earnings estimate was $0.02 per share on revenue of $87.6 million. Revenue grew 50.7% on a year-over-year basis.
Entry Point: $23.00
Stop Loss: $21.85
52-Week Trading Range: $11.05 to $24.30
Target Price: $25.30
NEO closed at $25.65
